CCL2 and permanent neonatal diabetes mellitus-pancreatic and cerebellar agenesis syndrome: Multiple studies have demonstrated that BA treatment significantly decreases VEGF [25], [28], [41]–[42], MCP-1 [25], [28] and TNF-α [28], [40], [43] in different animal model such as in LPS-challenged ApoE mice [25], [28], in a transgenic model of psoriasis [44], in an orthotopic nude mouse model of PaCa [41] and in a murine sponge model [43].